Brasada Capital Management LP Makes New Investment in Elanco Animal Health Incorporated $ELAN

Brasada Capital Management LP acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 30,010 shares of the company’s stock, valued at approximately $679,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Parallel Advisors LLC boosted its holdings in Elanco Animal Health by 5.9% in the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after purchasing an additional 392 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its holdings in Elanco Animal Health by 0.4% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after purchasing an additional 428 shares during the period. Meeder Advisory Services Inc. boosted its holdings in Elanco Animal Health by 4.8% in the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after purchasing an additional 510 shares during the period. Root Financial Partners LLC boosted its holdings in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares during the period. Finally, Legacy Capital Group California Inc. boosted its holdings in Elanco Animal Health by 3.1% in the fourth quarter. Legacy Capital Group California Inc. now owns 20,988 shares of the company’s stock worth $475,000 after purchasing an additional 632 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Transactions at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons acquired 4,971 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is owned by insiders.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $24.19 on Friday. Elanco Animal Health Incorporated has a 1 year low of $13.15 and a 1 year high of $27.72. The company has a market cap of $12.08 billion, a price-to-earnings ratio of -48.39, a price-to-earnings-growth ratio of 1.58 and a beta of 1.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The firm has a fifty day moving average of $22.90 and a 200-day moving average of $23.47.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the previous year, the company posted $0.37 earnings per share. The company’s revenue for the quarter was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ELAN. JPMorgan Chase & Co. boosted their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. KeyCorp boosted their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Finally, Citigroup boosted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average target price of $28.20.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.